MARKET

RDUS

RDUS

Radius Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.04
-0.51
-4.06%
After Hours: 12.04 0 0.01% 16:29 09/18 EDT
OPEN
12.69
PREV CLOSE
12.55
HIGH
12.71
LOW
11.78
VOLUME
969.76K
TURNOVER
--
52 WEEK HIGH
29.89
52 WEEK LOW
10.32
MARKET CAP
559.53M
P/E (TTM)
-4.0877
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile

Analyst Price Target

The average RDUS stock price target is 20.57 with a high estimate of 28.00 and a low estimate of 14.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About RDUS
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Radius Health Inc stock information, including NASDAQ:RDUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDUS stock methods without spending real money on the virtual paper trading platform.